Trinity Biotech has announced positive clinical trial results for its newly redesigned continuous glucose monitoring (CGM) sensor. The findings mark a major milestone for the company’s next-generation diabetes management technology, supporting its strategy to expand in the digital health and medical devices market.
Strong Outcomes from Clinical Study
The clinical trial demonstrated that Trinity Biotech’s redesigned CGM sensor achieved significantly improved accuracy and performance, meeting key safety and efficacy endpoints. The device is designed to provide continuous, real-time glucose data for people living with diabetes, enabling better control and reducing the risks of complications associated with fluctuating blood glucose levels.
The study’s outcomes support the sensor’s ability to compete with established CGM technologies while offering a user-friendly design and advanced features aimed at improving patient experience. Trinity Biotech plans to advance towards regulatory submissions and prepare for commercialisation.
Expanding Digital Health Portfolio
Building on its diagnostics expertise, Trinity Biotech is positioning itself as an emerging player in digital health and wearable medical technologies. The CGM platform is expected to create new revenue opportunities and strengthen its presence in the rapidly growing global diabetes care market.
CEO Statement
“These results confirm the potential of our redesigned CGM system to transform glucose monitoring,” said Trinity Biotech’s CEO. “We are excited to bring this next-generation technology closer to patients, helping them live healthier lives through better control of their diabetes.”
